Solvonis Therapeutics PLCLSE: SVNS

Solvonis Therapeutics: Holding(s) in Company

· Issued by Solvonis Therapeutics PLC via RNS

Summary by 6ix AI

Nicholas Christian Paul Nelson notified Solvonis Therapeutics Plc on October 15, 2026 that he held 205,961,538 voting rights (the votes attached to his shares), or 2.6%, as of September 30, 2026. His percentage changed after the company issued new shares, some of which were issued to him.

Key details

  • The notice was filed on a TR-1, the UK standard form for notifying major holdings, which is made when a holding crosses or reaches a reporting threshold. Here the threshold was crossed or reached on September 30, 2026.
  • The reason given for the notification is an event changing the breakdown of voting rights.
  • The holding consists of voting rights attached to shares, with no holdings reported through financial instruments.
  • He is not controlled by any person or entity and does not control any other undertaking holding an interest in Solvonis Therapeutics Plc.

6ix AI wrote this summary from the release below and checked it against the release.

Solvonis Therapeutics PLC
16 October 2026
 

TR-1: Standard form for notification of major holdings

1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached ii:

Solvonis Therapeutics Plc

1b. Please indicate if the issuer is a non-UK issuer  (please mark with an “X” if appropriate)

Non-UK issuer

2. Reason for the notification (please mark the appropriate box or boxes with an “X”)

An acquisition or disposal of voting rights

An acquisition or disposal of financial instruments

An event changing the breakdown of voting rights

x

Other (please specify) iii:

3. Details of person subject to the notification obligation iv

Name

Nicholas Christian Paul Nelson

City and country of registered office (if applicable)

4. Full name of shareholder(s) (if different from 3.) v

Name

City and country of registered office (if applicable)

5. Date on which the threshold was crossed or reached vi:

30/09/2026

6. Date on which issuer notified (DD/MM/YYYY):

15/10/2026

7. Total positions of person(s) subject to the notification obligation

% of voting rights attached to shares (total of 8. A)

% of voting rights through financial instruments
(total of 8.B 1 + 8.B 2)

Total of both in % (8.A + 8.B)

Total number of voting rights held in issuer (8.A + 8.B) vii

Resulting situation on the date on which threshold was crossed or reached

205,961,538

2.6

Position of previous notification (if

applicable)

205,961,538

8. Notified details of the resulting situation on the date on which the threshold was crossed or reached viii

A: Voting rights attached to shares

Class/type of
shares

ISIN code (if possible)

Number of voting rights ix

% of voting rights

Direct

(DTR5.1)

Indirect

 (DTR5.2.1)

Direct

(DTR5.1)

Indirect

(DTR5.2.1)

GB00BMD1Z199

205,961,538

2.6

SUBTOTAL 8. A

205,961,538

2.6

B 1: Financial Instruments according to DTR5.3.1R (1) (a)

Type of financial instrument

Expiration
date x

Exercise/
Conversion Period xi

Number of voting rights that may be acquired if the instrument is

exercised/converted.

% of voting rights

SUBTOTAL 8. B 1

B 2: Financial Instruments with similar economic effect according to DTR5.3.1R (1) (b)

Type of financial instrument

Expiration
date x

Exercise/
Conversion Period xi

Physical or cash

Settlement xii

Number of voting rights

% of voting rights

N/A

SUBTOTAL 8.B.2

9. Information in relation to the person subject to the notification obligation (please mark the

applicable box with an “X”)

Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuer xiii

x

Full chain of controlled undertakings through which the voting rights and/or the
financial instruments are effectively held starting with the ultimate controlling natural person or legal entity (please add additional rows as necessary) xiv

Name xv

% of voting rights if it equals or is higher than the notifiable threshold

% of voting rights through financial instruments if it equals or is higher than the notifiable threshold

Total of both if it equals or is higher than the notifiable threshold

10. In case of proxy voting, please identify:

Name of the proxy holder

The number and % of voting rights held

The date until which the voting rights will be held

11. Additional information xvi

Changed percentage is following an issue of new shares by the issuer plus the issue of some of those new shares to the person (above) subject to the notification

Place of completion

London, UK

Date of completion

15/10/2026

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 

Solvonis Therapeutics PLC on 6ix

Earlier from Solvonis Therapeutics

All Solvonis Therapeutics news releases